Network Meta-analysis of the Efficacy and Adverse Effects of Several Treatments for Advanced/metastatic Prostate Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Sep 24

PMID 28938674

Citations 3

Authors

Jing Wu

Wei-Kang Chen

Wei Zhang

Jin-Song Zhang

Jian-He Liu

Yong-Ming Jiang

Ke-Wei Fang

Affiliations

Soon will be listed here.

Abstract

This network meta-analysis was conducted to compare the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer (PC). The PubMed and Cochrane Library databases were searched for randomized controlled trials of treatments for advanced/metastatic PC. Eighteen studies covering 6,340 patients were included in this analysis. The calculated were odds ratios, 95% confidence intervals, and the surface under the cumulative ranking (SUCRA) curve. Pairwise meta-analysis showed that overall survival rates achieved with radiotherapy or endocrine therapy were lower than obtained with radiotherapy + endocrine therapy. The endocrine therapy includes estrogen therapy, luteinizing hormone-releasing hormone agonist (LHRH-A), anti-androgen therapy (ADT), ADT + LHRH-A and estrogen therapy + LHRH-A, and its SUCRA values indicated that for overall response rate, estrogen therapy + LHRH-A ranked the highest (92.6%); for overall survival rate, ADT ranked the highest (75.2%); for anemia, estrogen therapy ranked the highest (88.2%); and for diarrhea and hot flushes, ADT ranked the highest (diarrhea, 87.4%; hot flushes, 89.3%). Cluster analysis on the endocrine therapy showed that ADT + LHRH-A achieved the highest overall survival and overall response rates in the treatment of advanced/metastatic PC. Estrogen therapy and ADT had the lowest incidences of diarrhea and anemia. Thus, combined radiotherapy + endocrine therapy had higher overall survival rate, and among the endocrine therapy, in terms of overall response rate and overall survival rate, ADT + LHRH-A may be a better regimen in the treatment of advanced or metastatic PC.

Citing Articles

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials.

Luo Z, Zhu B, Xu H, Chen L, Song X, Wang Y Front Oncol. 2023; 13:1265276.

PMID: 37869079 PMC: 10587563. DOI: 10.3389/fonc.2023.1265276.

Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

von Eyben F, Kairemo K, Paller C, Hoffmann M, Paganelli G, Virgolini I Biomedicines. 2021; 9(8).

PMID: 34440246 PMC: 8392412. DOI: 10.3390/biomedicines9081042.

Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis.

Dai D, Han S, Li L, Guo Y, Wei Y, Jin H Am J Transl Res. 2019; 10(12):3877-3886.

PMID: 30662637 PMC: 6325522.

References

Denham J, Steigler A, Lamb D, Joseph D, Turner S, Matthews J . Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011; 12(5):451-9. DOI: 10.1016/S1470-2045(11)70063-8. View

Furr B . "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies. Horm Res. 1989; 32 Suppl 1:69-76. DOI: 10.1159/000181315. View

Trock B, Han M, Freedland S, Humphreys E, DeWeese T, Partin A . Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299(23):2760-9. PMC: 3076799. DOI: 10.1001/jama.299.23.2760. View

Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood Jr D . Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995; 154(2 Pt 1):424-8. View

Overgaard M, Jensen M, Overgaard J, Hansen P, Rose C, Andersson M . Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999; 353(9165):1641-8. DOI: 10.1016/S0140-6736(98)09201-0. View

van der Klift M, de Laet C, McCloskey E, Hofman A, Pols H . The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002; 17(6):1051-6. DOI: 10.1359/jbmr.2002.17.6.1051. View

Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A . Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 1996; 56 Suppl 1:13-7. DOI: 10.1159/000282863. View

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

Shingler E, Hackshaw-McGeagh L, Robles L, Persad R, Koupparis A, Rowe E . The feasibility of the Prostate cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) dietary and physical activity modifications: a qualitative study. Trials. 2017; 18(1):106. PMC: 5340012. DOI: 10.1186/s13063-017-1828-4. View

10.

Mason M, Parulekar W, Sydes M, Brundage M, Kirkbride P, Gospodarowicz M . Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol. 2015; 33(19):2143-50. PMC: 4477786. DOI: 10.1200/JCO.2014.57.7510. View

11.

Salanti G, Ades A, Ioannidis J . Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010; 64(2):163-71. DOI: 10.1016/j.jclinepi.2010.03.016. View

12.

Widmark A, Klepp O, Solberg A, Damber J, Angelsen A, Fransson P . Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2008; 373(9660):301-8. DOI: 10.1016/S0140-6736(08)61815-2. View

13.

McLeod . Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer. Oncologist. 1997; 2(1):18-27. View

14.

Chen L, Li Y, Ning G, Li Y, Wu Q, Guo J . Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review. PLoS One. 2015; 10(4):e0123153. PMC: 4395314. DOI: 10.1371/journal.pone.0123153. View

15.

Gardsell P, Johnell O, NILSSON B . The predictive value of forearm bone mineral content measurements in men. Bone. 1990; 11(4):229-32. DOI: 10.1016/8756-3282(90)90074-9. View

16.

Chaimani A, Higgins J, Mavridis D, Spyridonos P, Salanti G . Graphical tools for network meta-analysis in STATA. PLoS One. 2013; 8(10):e76654. PMC: 3789683. DOI: 10.1371/journal.pone.0076654. View

17.

Colvard D, Eriksen E, Keeting P, Wilson E, Lubahn D, French F . Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A. 1989; 86(3):854-7. PMC: 286576. DOI: 10.1073/pnas.86.3.854. View

18.

Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K . Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004; 11(2):103-9. DOI: 10.1111/j.1442-2042.2004.t01-1-00748.x. View

19.

Chung J, Lee S . Assessing the quality of randomized controlled urological trials conducted by korean medical institutions. Korean J Urol. 2013; 54(5):289-96. PMC: 3659221. DOI: 10.4111/kju.2013.54.5.289. View

20.

Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O . Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996; 14(8):2250-7. DOI: 10.1200/JCO.1996.14.8.2250. View